Carolina Terragna

Bologna, 40138, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework.

Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 06, 2026

Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.

Comparative Analysis Between the EuroClonality-NGS Approach and the LymphoTrack® Dx Assay for IG/TR Marker Screening in Lymphoid Leukemias: A Campus ALL Study.

Journal: International journal of molecular sciences

Published: April 24, 2026

Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience.

Journal: Cancer medicine

Published: October 07, 2025

Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.

Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma.

Journal: Frontiers in oncology

Published: July 24, 2025

AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy.

AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy.

Journal: Scientific reports

Published: July 03, 2025

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma.

Journal: HemaSphere

Published: June 16, 2025

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal: Journal of cancer research and clinical oncology

Published: May 14, 2025

Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.

Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.

Journal: Haematologica

Published: February 16, 2025

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.

Journal: International journal of molecular sciences

Published: July 30, 2024

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.

Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients.

Journal: Cancers

Published: July 10, 2024

Genomic landscape of multiple myeloma and its precursor conditions.

Genomic landscape of multiple myeloma and its precursor conditions.

Journal: Nature genetics

Published: July 04, 2024

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.

Journal: Blood cancer journal

Published: July 01, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026